Hansa Biopharma announces ConfIdeS Phase 3 Abstract Selected for ‘What’s Hot, What’s New’ Plenary at ATC 2026

Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that the ConfIdeS Phase 3 abstract titled “Superior 1-year eGFR Among Highly Sensitized Patients Desensitized with Imlifidase Compared to Control” has been selected to be highlighted at the closing plenary session “What’s Hot, What’s New” at the American Transplant Congress (ATC) 2026, taking place in Boston on June 24, 2026.

Renée Aguiar-Lucander, CEO of Hansa Biopharma, said: “This recognition highlights the strength and clinical relevance of the ConfIdeS data and the potential of imlifidase to address a significant unmet need in highly sensitized transplant patients. Being selected for the ‘What’s Hot, What’s New’ plenary session underscores the novelty and importance of these findings for the transplant community.”

ATC is the leading annual meeting in transplantation, bringing together experts to share the latest scientific and clinical advances in the field. The “What’s Hot, What’s New” closing plenary session showcases a select group of abstracts considered to represent some of the most notable and impactful scientific contributions presented at the congress.

The inclusion of the ConfIdeS abstract in this session follows its prior selection as a late-breaking oral presentation at ATC 2026, further emphasizing the growing scientific and clinical interest in imlifidase and its potential role in enabling kidney transplantation in highly sensitized patients.

The presentation includes detailed 12-month results from the ConfIdeS trial, including the primary endpoint eGFR, key secondary endpoints as well as safety results. The presentation was delivered by Dr. Robert Montgomery, MD PhD, New York University Langone Transplant Institute, on behalf of the ConfIdeS study group.